切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2024, Vol. 13 ›› Issue (04) : 213 -218. doi: 10.3877/cma.j.issn.2095-3216.2024.04.006

综述

基于临床化验指标重新计算的生物标记物在预测腹膜透析患者预后中的作用研究进展
张晓青1, 唐雯1,()   
  1. 1. 100191 北京大学第三医院肾内科
  • 收稿日期:2023-11-30 出版日期:2024-08-28
  • 通信作者: 唐雯
  • 基金资助:
    北京大学第三医院队列建设项目(BYSYDL2023004)

Research advance in the role of predicting the prognosis of peritoneal dialysis patients by recalculated biomarkers based on clinical laboratory indicators

Xiaoqing Zhang1, Wen Tang1,()   

  1. 1. Department of Nephrology, Peking University Third Hospital, Beijing 100191, China
  • Received:2023-11-30 Published:2024-08-28
  • Corresponding author: Wen Tang
引用本文:

张晓青, 唐雯. 基于临床化验指标重新计算的生物标记物在预测腹膜透析患者预后中的作用研究进展[J]. 中华肾病研究电子杂志, 2024, 13(04): 213-218.

Xiaoqing Zhang, Wen Tang. Research advance in the role of predicting the prognosis of peritoneal dialysis patients by recalculated biomarkers based on clinical laboratory indicators[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(04): 213-218.

炎症及免疫、营养状态受损是腹膜透析患者预后不良的危险因素。由于炎症、免疫及营养之间关系错综复杂,复合生物标记物可能较单一生物标志物具有较佳的临床预后预测能力。近期研究表明,一些基于临床化验指标重新计算的生物标记物简单易得,可以较好反映身炎症、免疫及营养状态,对腹膜透析患者的结局有较好预测作用。本文综述了基于临床化验指标重新计算的生物标记物在预测腹膜透析患者预后中的作用研究进展,以期为临床腹膜透析患者的危险度分层与管理提供新思路。

Inflammation and impairment of immunity and nutrition are risk factors for poor prognosis in peritoneal dialysis patients. Due to the complex relationship among inflammation, immunity, and nutrition, composite biomarkers may have better clinical prognostic predictive ability than a single biomarker. Current research indicated that some biomarkers recalculated based on clinical laboratory indicators were simple and easy to obtain, which might have a better role in reflecting the status of inflammation, immunity, and nutrition, and in predicting the outcomes of peritoneal dialysis patients. This article reviewed the research progress on the role of biomarkers based on recalculated clinical laboratory indicators in predicting the prognosis of peritoneal dialysis patients, in order to provide new ideas for risk stratification and management of clinical peritoneal dialysis patients.

表1 中性粒细胞与淋巴细胞比在预测腹膜透析患者预后中的研究进展
[1]
Xu XD, Han X, Yang Y, et al. Comparative study on the efficacy of peritoneal dialysis and hemodialysis in patients with end-stage diabetic nephropathy [J]. Pak J Med Sci, 2020, 36(7): 1484-1489.
[2]
Thurlow JS, Joshi M, Yan G, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy [J]. Am J Nephrol, 2021, 52(2): 98-107.
[3]
Xiang F, Chen R, Cao X, et al. Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study [J]. Hemodial Int, 2018, 22(1): 82-92.
[4]
Yang N, Yang K, Pan S, et al. Progress in the application of the neutrophil-to-lymphocyte ratio in dialysis-related complications [J]. Ren Fail, 2023, 45(2): 2259996.
[5]
Núñez J, Sanchis J, Bodí V, et al. Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal troponin levels [J]. Atherosclerosis, 2009, 206(1): 251-257.
[6]
Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy [J]. Sci Rep, 2021, 11(1): 14662.
[7]
Duan Y, Peng Z, Zhong S, et al. Association between subclinical left ventricular ejection fraction and platelet-to-lymphocyte ratio in patients with peritoneal dialysis [J]. Front Med (Lausanne), 2022, 9: 961453.
[8]
Angkananard T, Anothaisintawee T, McEvoy M, et al. Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis [J]. Biomed Res Int, 2018, 2018: 2703518.
[9]
Lu X, Wang S, Zhang G, et al. High neutrophil-to-lymphocyte ratio is a significant predictor of cardiovascular and all-cause mortality in patients undergoing peritoneal dialysis [J]. Kidney Blood Press Res, 2018, 43(2): 490-499.
[10]
Zhang L, Nie Y, Guo M, et al. Neutrophil to lymphocyte ratio as a predictor of long-term outcome in peritoneal dialysis patients: a 5-Year cohort study [J]. Blood Purif, 2021, 50(6): 772-778.
[11]
Zeng Y, Chen Z, Chen Q, et al. Neutrophil to lymphocyte ratio predicts adverse cardiovascular outcome in peritoneal dialysis patients younger than 60 years old [J]. Mediators Inflamm, 2020, 2020: 4634736.
[12]
Lau LFS, Ng JKC, Fung WWS, et al. Relationship between serial serum neutrophil-lymphocyte ratio, cardiovascular mortality, and all-cause mortality in Chinese peritoneal dialysis patients [J]. Kidney Blood Press Res, 2023, 48(1): 414-423.
[13]
Cai K, Luo Q, Zhu B, et al. Neutrophil-lymphocyte ratio is associated with arterial stiffness in patients with peritoneal dialysis [J]. BMC Nephrol, 2016, 17(1): 191.
[14]
Guo G, Zeng Y, Chen Q, et al. High neutrophil/lymphocyte ratio as an independent risk factor for the first occurrence of stroke in peritoneal dialysis patients [J]. Iran J Kidney Dis, 2020, 14(4): 282-289.
[15]
He P, He LJ, Huang C, et al. Neutrophil-to-lymphocyte ratio and treatment failure in peritoneal dialysis-associated peritonitis [J]. Front Med (Lausanne), 2021, 8: 699502.
[16]
Fung WW, Chow KM, Ng JK, et al. The clinical utility of the neutrophil-to-lymphocyte ratio as a discriminatory test among bacterial, mycobacterium tuberculosis, and nontuberculous mycobacterium peritoneal dialysis-related peritonitis [J]. Kidney360, 2022, 3(6): 1031-1038.
[17]
Zhang Y, Lai X, Chen Q, et al. The relationship between neutrophil-to-lymphocyte ratio and the first occurrence of pneumonia in peritoneal dialysis patients [J]. Clin Exp Nephrol, 2020, 24(9): 770-778.
[18]
Seo IH, Lee YJ. Usefulness of complete blood count (CBC) to assess cardiovascular and metabolic diseases in clinical settings: a comprehensive literature review [J]. Biomedicines, 2022, 10(11): 2697.
[19]
Chen T, Yang M. Platelet-to-lymphocyte ratio is associated with cardiovascular disease in continuous ambulatory peritoneal dialysis patients [J]. Int Immunopharmacol, 2020, 78: 106063.
[20]
Sheng H, Qiu Y, Xia X, et al. Sexual effect of platelet-to-lymphocyte ratio in predicting cardiovascular mortality of peritoneal dialysis patients [J]. Mediators Inflamm, 2022, 2022: 8760615.
[21]
Liu S, Yang M, Zhao Q, et al. Platelet-to-lymphocyte ratio is associated with the mortality in peritoneal dialysis patients [J]. Iran J Kidney Dis, 2021, 15(3): 206-212.
[22]
Su N, Zheng Y, Zhang X, et al. Platelet-to-lymphocyte ratio and the first occurrence of peritonitis in peritoneal dialysis patients [J]. BMC Nephrol, 2022, 23(1): 415.
[23]
Zhou D, Yang H, Zeng L, et al. Calculated inflammatory markers derived from complete blood count results, along with routine laboratory and clinical data, predict treatment failure of acute peritonitis in chronic peritoneal dialysis patients [J]. Ren Fail, 2023, 45(1): 2179856.
[24]
Wen Y, Zhan X, Wang N, et al. Monocyte/lymphocyte ratio and cardiovascular disease mortality in peritoneal dialysis patients [J]. Mediators Inflamm, 2020, 2020: 9852507.
[25]
Yang Y, Xu Y, Lu P, et al. The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients [J]. Eur J Med Res, 2023, 28(1): 152.
[26]
Varol E, Ozaydin M. Mean platelet volume measurement in chronic renal failure: confounding factors must have been taken into account [J]. Ren Fail, 2014, 36(3): 488.
[27]
Wang J, Ma X, Si X, et al. Mean platelet volume and the association with all-cause mortality and cardiovascular mortality among incident peritoneal dialysis patients [J]. BMC Cardiovasc Disord, 2023, 23(1): 543.
[28]
Chen J, Zhong Z, Li J, et al. Effect of mean platelet volume to platelet count ratio on mortality in peritoneal dialysis [J]. Mediators Inflamm, 2022, 2022: 6922809.
[29]
Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M, et al. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro [J]. J Thromb Thrombolysis, 2010, 30(3): 251-262.
[30]
Peng F, Li Z, Yi C, et al. Platelet index levels and cardiovascular mortality in incident peritoneal dialysis patients: a cohort study [J]. Platelets, 2017, 28(6): 576-584.
[31]
Deng Q, Long Q, Liu Y, et al. Prognostic value of preoperative peripheral blood mean platelet volume/platelet count ratio (MPV/PC) in patients with resectable cervical cancer [J]. BMC Cancer, 2021, 21(1): 1282.
[32]
Ösken A, Hacı R, Dinç Asarcıklı L, et al. Mean platelet volume/platelet count ratio as a predictor of stent thrombosis in patients with ST-segment-elevation myocardial infarction [J]. Ir J Med Sci, 2021, 190(3): 1095-1102.
[33]
Lin YC, Jan HC, Ou HY, et al. Low preoperative mean platelet volume/platelet count ratio indicates worse prognosis in non-metastatic renal cell carcinoma [J]. J Clin Med, 2021, 10(16): 3676.
[34]
Zhu Y, Peng F, Chen Y, et al. Mean platelet volume/platelet count ratio and mortality in patients on peritoneal dialysis [J]. Clin Nephrol, 2018, 90(3): 205-211.
[35]
Kim S, Molnar MZ, Fonarow GC, et al. Mean platelet volume and mortality risk in a national incident hemodialysis cohort [J]. Int J Cardiol, 2016, 220: 862-870.
[36]
Valero C, Pardo L, Sansa A, et al. Prognostic capacity of systemic inflammation response index (SIRI) in patients with head and neck squamous cell carcinoma [J]. Head Neck, 2020, 42(2): 336-343.
[37]
Li J, Li Y, Zou Y, et al. Use of the systemic inflammation response index (SIRI) as a novel prognostic marker for patients on peritoneal dialysis [J]. Ren Fail, 2022, 44(1): 1227-1235.
[38]
Yang Y, Xu Y, Liu S, et al. The systemic inflammation indexes predict all-cause mortality in peritoneal dialysis patients [J]. Ren Fail, 2023, 45(1): 2160348.
[39]
Zhang F, Li L, Wu X, et al. Pan-immune-inflammation value is associated with poor prognosis in patients undergoing peritoneal dialysis [J]. Ren Fail, 2023, 45(1): 2158103.
[40]
Li G, Yu J, Jiang S, et al. Systemic immune-inflammation index was significantly associated with all-cause and cardiovascular-specific mortalities in patients receiving peritoneal dialysis [J]. J Inflamm Res, 2023, 16: 3871-3878.
[41]
Kaysen GA. Biological basis of hypoalbuminemia in ESRD [J]. J Am Soc Nephrol, 1998, 9(12): 2368-2376.
[42]
Spiegel DM, Breyer JA. Serum albumin: a predictor of long-term outcome in peritoneal dialysis patients [J]. Am J Kidney Dis, 1994, 23(2): 283-285.
[43]
Peng F, Chen W, Zhou W, et al. Low prognostic nutritional index associated with cardiovascular disease mortality in incident peritoneal dialysis patients [J]. Int Urol Nephrol, 2017, 49(6): 1095-1101.
[44]
Yang Y, Zhou H, Zhang P, et al. Evaluation of objective nutritional indexes as predictors of worse outcomes in peritoneal dialysis patients [J]. Nutrition, 2020, 79-80: 110963.
[45]
Yang Y, Xu Y, Zhang P, et al. Predictive value of objective nutritional indexes in technique failure in peritoneal dialysis patients [J]. J Ren Nutr, 2022, 32(5): 605-612.
[46]
Huang Y, Zhang X, Tang X, et al. A low prognostic nutritional index is a risk factor for high peritoneal transport status in patients undergoing peritoneal dialysis [J]. J Ren Nutr, 2023, 33(1): 201-207.
[47]
Shang S, Huang Y, Zhan X, et al. The relationship between the prognostic nutritional index and new-onset pneumonia in peritoneal dialysis patients [J]. Int Urol Nephrol, 2022, 54(11): 3017-3024.
[48]
Zhou H, Chao W, Cui L, et al. Controlling nutritional status (CONUT) score as immune-nutritional predictor of outcomes in patients undergoing peritoneal dialysis [J]. Clin Nutr, 2020, 39(8): 2564-2570.
[49]
Ren M, Sheng Q, Xie X, et al. Geriatric nutritional risk index is associated with mortality in peritoneal dialysis patients [J]. Intern Med J, 2020, 50(4): 470-476.
[50]
Szeto CC, Kwan BC, Chow KM, et al. Geriatric nutritional risk index as a screening tool for malnutrition in patients on chronic peritoneal dialysis [J]. J Ren Nutr, 2010, 20(1): 29-37.
[51]
Yu J, Xia X, Lin T, et al. Non-high-density lipoprotein cholesterol and mortality among peritoneal dialysis patients [J]. J Clin Lipidol, 2021, 15(5): 732-742.
[52]
Wu J, Yang R, Wang X, et al. Total cholesterol and mortality in peritoneal dialysis: a retrospective cohort study [J]. BMC Nephrol, 2023, 24(1): 142.
[53]
Zhan X, Pan D, Wei X, et al. Monocyte to high-density lipoprotein ratio and cardiovascular events in patients on peritoneal dialysis [J]. Nutr Metab Cardiovasc Dis, 2020, 30(7): 1130-1136.
[54]
Chen J, Zhong Z, Shi D, et al. Association between monocyte count to high-density lipoprotein cholesterol ratio and mortality in patients undergoing peritoneal dialysis [J]. Nutr Metab Cardiovasc Dis, 2021, 31(7): 2081-2088.
[55]
Lin T, Xia X, Yu J, et al. The predictive study of the relation between elevated low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality in peritoneal dialysis [J]. Lipids Health Dis, 2020, 19(1): 51.
[56]
Noh HW, Jeon Y, Kim JH, et al. Higher serum total cholesterol to high-density lipoprotein cholesterol ratio is associated with increased mortality among incident peritoneal dialysis patients [J]. Nutrients, 2021, 14(1): 144.
[57]
Liu S, Qiu P, Luo L, et al. Serum C-reactive protein to albumin ratio and mortality associated with peritoneal dialysis [J]. Ren Fail, 2020, 42(1): 600-606.
[58]
Guo M, Sun T, Zhao Z, et al. Preoperative platelet to albumin ratio predicts outcome of patients with nonα-SMABll-cell lung cancer [J]. Ann Thorac Cardiovasc Surg, 2021, 27(2): 84-90.
[59]
Yang Y, Yuan J, Liu L, et al. Platelet-to-albumin ratio: a risk factor associated with technique failure and mortality in peritoneal dialysis patients [J]. Ren Fail, 2021, 43(1): 1359-1367.
[60]
Xia W, Kuang M, Li C, et al. Prognostic significance of the albumin to fibrinogen ratio in peritoneal dialysis patients [J]. Front Med (Lausanne), 2022, 9: 820281.
[61]
Tsai CC, Hsieh YP, Tsai SM, et al. Superiority of albumin–globulin ratio over albumin to predict mortality in patients undergoing peritoneal dialysis [J]. Sci Rep, 2020, 10(1): 19764.
[62]
Zhan C, Peng Y, Ye H, et al. Triglyceride glucose-body mass index and cardiovascular mortality in patients undergoing peritoneal dialysis: a retrospective cohort study [J]. Lipids Health Dis, 2023, 22(1): 143.
[1] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J]. 中华医学超声杂志(电子版), 2024, 21(04): 361-369.
[2] 孙勇, 彭曦. 重视烧伤创面愈合中的葡萄糖代谢以优化营养治疗策略[J]. 中华损伤与修复杂志(电子版), 2024, 19(04): 277-281.
[3] 刘炯, 彭乐, 马伟, 江斌. 鞘外解剖肝蒂技术治疗肝内胆管细胞癌的疗效评估[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 373-376.
[4] 翟刚, 邓修民, 岑川, 黄锋, 黄显壮, 王运成. 改良双通道吻合法在完全腹腔镜近端胃切除术中的临床效果研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 397-400.
[5] 李勇, 彭天明, 王倩倩, 陈育纯, 蒲小勇, 刘久敏. 基于失巢凋亡相关基因的膀胱癌预后模型构建及分析[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 331-339.
[6] 李飞, 郑灶松, 吴芃, 谭万龙. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——延胡索酸水合酶缺陷型晚期肾细胞癌[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 410-414.
[7] 王天福, 王刚. 自身免疫性胰腺炎诊治现状[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 492-497.
[8] 龚财芳, 赵俊宇, 游川. 围手术期肠内营养在肝癌肝切除患者中有效性及安全性的Meta分析[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 551-556.
[9] 张杰, 田广磊, 陈雄. 基于生物信息学分析探讨肝癌BRD4与预后关系及其ceRNA调控网络构建[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 568-576.
[10] 朱军, 宋家伟, 乔一桓, 郭雅婕, 刘帅, 姜玉, 李纪鹏. M2型巨噬细胞特征基因与结肠癌免疫微环境研究[J]. 中华结直肠疾病电子杂志, 2024, 13(04): 303-311.
[11] 田娜, 韩飞天. 基于CT平扫影像组学模型与系统免疫炎症指数预测急性胰腺炎复发模型的建立[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 355-359.
[12] 唐小久, 胡曼, 许必君, 肖亚. 肥胖合并胃食管反流病患者严重程度与其焦虑抑郁及营养状态的相关性研究[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 360-364.
[13] 李秀玲, 连少锋, 荣刘涛, 李登峰, 饶蕴玉. 利巴韦林联合复方嗜酸乳杆菌治疗轮状病毒肠炎患儿的临床研究[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 369-372.
[14] 谭欣, 王鹏源, 胡良皞. 慢性胰腺炎抗炎和抗纤维化治疗的研究进展[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 289-296.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要